Mexico: Recent Developments In Clinical Data Exclusivity

Evolution of data exclusivity

Mexico, along with the United States and Canada, was one of the first countries to sign data protection provisions in a free trade agreement. The North American Free Trade Agreement (NAFTA) included obligations related to the protection of data submitted before regulatory agencies well before the Agreement on Trade-Related Aspects of IP Rights (TRIPs).

Paragraphs 5 to 7 of Article 1711 of NAFTA contain specific provisions with regard to data submitted to entities in charge of granting market approvals for pharmaceutical and agrochemical products, with the main obligation imposed on the contracting states to prevent unfair commercial use of such information. NAFTA has always been considered a more specific standard for the protection of clinical data than TRIPs, as it provides for a minimum standard of five years of protection from the date that market authorisation was granted.

However, such paragraphs are not as clear as intended, allowing compliance with the treaty by simply keeping the information confidential. Mexico has enacted no specific national provisions that could facilitate the interpretation or implementation of the treaty. The only reference to the treaty is included in the Industrial Property Law, which states in Article 86bis that any information required for determining safety and efficacy of pharmaceutical and agrochemical products using novel chemical compounds will be protected under the terms of the international treaties to which Mexico is party.

For many years, the results of clinical trials submitted to the health authorities were not published or otherwise made available to the public. The government argued that this was in compliance with the treaties because the information collected was kept confidential. In fact, not a single case of grant of a generic drug approval (before the five¬year period mentioned in TRIPs and NAFTA) had been documented, perhaps because of the existence of patents covering longer periods.

Accordingly, data exclusivity enforcement in Mexico was theoretically difficult because not all drugs commercialised after a first approval required bioequivalence tests – that is, the so¬called ‘lookalikes’. Mexico was technically not obliged to prevent unfair commercial use because the information for the drug that had been approved first was not publicly available from the Federal Commission for the Protection against Sanitary Risk and therefore not ‘used’ by generic manufacturers.

Since February 2008, modifications to the Health Supplies Regulations have led to the elimination of lookalikes and interchangeable generics, for which registration was based on general public data, by providing for only two kinds of drug:

  • innovator drugs, based on information from clinical trials; and
  • generic drugs, based on bioequivalence tests without the need for full clinical trials.

Although growing concerns regarding the quality of lookalikes drove these changes, inadvertently they also made applicable one of the specific rules under NAFTA for the fiveyear protection term.

NAFTA provides for the data exclusivity of bioequivalence testing because the grant of generic drugs based on such testing is expressly included as possible if the fiveyear protection term is granted. However, the enactment of specific laws supporting such interpretation was still missing, as there were no court or administrative precedents that could support such an interpretation.

In practice, there were still no cases of grants of generic drug approvals within five years of the date of first registration of a drug in Mexico, although there have been attempts that are still under litigation. However, under new definitions incorporated into Mexican law, ‘innovator medicaments’ were defined as medicaments using or constituting new molecules, combinations of drugs that were not used formerly in Mexico, new indications or new formulations – all of which required the generation of clinical data and therefore, in principle, were protected by NAFTA.

The law further included the enactment of provisions related to biotechnology drugs and biocomparable (biosimilar) drugs. However, no provisions were raised regarding the possibility of a higher term of protection for such drugs.

Congress made some effort to compile an amendment regulating NAFTA and TRIPs obligations in the General Law on Health by considering a longer term of between 8 and 12 years for biotechnology drugs. Under the provisions related to such drugs, biotechnology drugs were considered simply as traditional chemical drugs with no differentiated treatment. With the recent change in government, the negotiations on such an amendment to the law were halted.

However, as the G20 forum was held in Mexico in June 2012 and Mexico wanted to enter negotiations for the TransPacific Strategic Economic Partnership Agreement, the government was urged to deal with three important pending IP issues:

  • the Madrid Protocol;
  • the Anticounterfeiting Trade Agreement; and
  • data exclusivity for pharmaceutical products.

In terms of data exclusivity for pharmaceutical products in particular, as the obligation of international treaties is imposed on contracting states, the government decided to enact such provisions through a set of internal rules that are mandatory only for officers of the Federal Commission for the Protection against Sanitary Risk.

New rules

The Guidelines for the Protection of Confidential Information of Medicines containing Pharmochemicals as a New Chemical Entity were published on June 18 2012. The Federal Commission for the Protection against Sanitary Risk expressly stated that the confidential information received in conjunction with a health approval application is subject to protection against unfair commercial use and public disclosure according to NAFTA and TRIPs. Such information is subject to a fiveyear term of data protection in Mexico from the date that approval is granted.

As already mentioned, as a matter of law, these guidelines are mandatory only for officers of the Federal Commission for the Protection against Sanitary Risk, but are not necessarily applicable in general to applicants applying for either new drugs or generic drug approvals, since they have only internal effects.

The guidelines expressly refer to Article 167 of the Health Supplies Regulations, which relates to data subject to protection according to international treaties. This article in turn describes the requirement to submit scientifically evidenced safety and efficacy data, which is therefore now recognised as subject to protection under the treaties for the first time in Mexico since NAFTA was signed.

On the other hand, the guidelines place a burden on the data owner of determinations that correspond to the Federal Commission for the Protection against Sanitary Risk. For example, the guidelines state that protection will be granted if the applicant proves that the submitted data relates to pharmochemical products that:

  • use “new chemical components”;
  • are related to safety and efficacy under the Health Supplies Regulations;
  • remain unpublished or were published in order to protect the public;
  • were protected against unfair commercial use by certain measures; and
  • the data for which was obtained through considerable effort.

It seems that the rules intended for internal officers of the Federal Commission for the Protection against Sanitary Risk place a burden on the applicant of a sanitary registration of a new drug, since on the one hand, officers must evaluate the submitted data, but on the other hand, submission of such data by the applicant of a new drug approval is not mandatory.

For biocomparable drugs, the guidelines refer only to Article 167 of the Health Supplies Regulations, without mentioning Article 177, which refers to data requested for the approval of biotechnology medicaments.

The drafting of the rules in the form of guidelines seems to have the intention of specifically excluding data related to formulations or new indications and also all data related to biocomparable drugs. The omission of Article 177 and the emphasis on the terms ‘new chemical component’ and ‘new chemical entity’ in the guidelines seem to support such an approach by the Federal Commission for the Protection against Sanitary Risk.

However, due to the different definitions used in the guidelines and the lack of consistency resulting from the use of terms that were not defined under applicable Mexican law, other interpretations seem possible and the final effect is yet to be determined.

One such inconsistency relates to Articles 166(III) and 2 of the Health Supplies Regulations. Under this law, medicaments for which safety and efficacy must be demonstrated based on information from clinical trials are those containing ‘new molecules’. The term, as mentioned above, comprises new molecular entities, but also drugs or combinations of drugs that were not used previously in Mexico, new indications or new formulations. Therefore, it might be possible to interpret that the terms ‘new chemical component’ and ‘new chemical entity’ are synonymous with the term ‘new molecule’, as this is the only term defined as such in Mexican law. However, this is not a straightforward issue.

The guidelines further fail to clarify the scope and nature of the protection resulting from a mix of language and concepts that are inconsistent with Mexican law ¬ for example, use of the terms ‘pharmochemical products’, ‘pharmochemical medicines’ and ‘new chemical components’ instead of the clearly defined term contained in Article 221 of the Law on Health: ‘medicament’.

The terms ‘pharmochemical products’ and ‘pharmochemical medicines’ are groundless, since they are undefined within the law; therefore, it is open to debate whether the regulations are illegal, since they contemplate terms that are not established in Mexican law, TRIPs or NAFTA. Likewise, the term ‘new chemical component’ is used indistinctly with the term ‘new chemical entity’, instead of ‘new molecule’ – a term also expressly defined in the Law on Health. This situation has led to discussions regarding the real intention of the guidelines when these different terms were cited.

What to expect

As explained above, the rules do not seem to clarify and implement in full the scope of NAFTA or TRIPs provisions. Instead, the new guidelines generate uncertainties that formerly did not exist, such as the term for biotechnology drugs (if any) and the applicability of the protection to data other than for new chemical components.

Therefore, there is still the need for a specific amendment that can consider all of the aspects of an efficient implementation of both treaties (ie, NAFTA and TRIPs), perhaps through amendments which align the guidelines with Mexican law by enacting a specific law regarding compliance with the treaties. Such an amendment must be executed directly into the law, or at least into the regulations, but not simply through internal regulations that are applicable only to the Federal Commission for the Protection against Sanitary Risk (as occurred with these new rules); otherwise, the nature and legality of the disposition that contemplates the date exclusivity provisions will always be a point of debate.

As the guidelines are implemented and used by officers of the Federal Commission for the Protection against Sanitary Risk in their decisions, litigation from generic manufacturers and affected data owners may arise which challenge the regulations per se or also challenge decisions issued by the commission grounded on this guidelines, under the main argument that internal dispositions cannot be applied to the general public.

In addition, it is also probable that the application of these guidelines will result in litigation claiming lack of clarity in the scope of the guidelines and in the language and wording of the provisions. Litigation might arise from both innovators and generics, depending on the way that the commission interprets the provisions. This seems to be the most likely scenario, considering that with the change of government in Mexico, the passing of the law that is still pending in Congress seems unlikely.

However, as TransPacific Strategic Economic Partnership Agreement negotiations progress and the obligations related to IP enforcement and compliance advance, we may also see some willingness from the government towards more specific implementation, with the main aim being a clear position regarding biotechnology drugs.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
Related Articles
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions